126 related articles for article (PubMed ID: 33894304)
1. Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma.
Witzigmann D; Grossen P; Quintavalle C; Lanzafame M; Schenk SH; Tran XT; Englinger B; Hauswirth P; Grünig D; van Schoonhoven S; Krähenbühl S; Terracciano LM; Berger W; Piscuoglio S; Quagliata L; Rommelaere J; Nüesch JPF; Huwyler J
J Control Release; 2021 Jun; 334():138-152. PubMed ID: 33894304
[TBL] [Abstract][Full Text] [Related]
2. Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1.
Hauswirth P; Graber P; Buczak K; Mancuso RV; Schenk SH; Nüesch JPF; Huwyler J
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680249
[TBL] [Abstract][Full Text] [Related]
3. Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma.
Liu C; Wen C; Wang X; Wei Y; Xu C; Mu X; Zhang L; Wang X; Tian J; Ma P; Meng F; Zhang Q; Zhao N; Yu B; Gong T; Guo R; Wang H; Xie J; Sun G; Li G; Zhang H; Qin Q; Xu J; Dong X; Wang L
Exp Cell Res; 2019 Oct; 383(1):111496. PubMed ID: 31306654
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.
Mullick Chowdhury S; Wang TY; Bachawal S; Devulapally R; Choe JW; Abou Elkacem L; Yakub BK; Wang DS; Tian L; Paulmurugan R; Willmann JK
J Control Release; 2016 Sep; 238():272-280. PubMed ID: 27503707
[TBL] [Abstract][Full Text] [Related]
7. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
8. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma.
Sawahara H; Shiraha H; Uchida D; Kato H; Kato R; Oyama A; Nagahara T; Iwamuro M; Horiguchi S; Tsutsumi K; Mandai M; Mimura T; Wada N; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Yagi T; Nasu Y; Kumon H; Okada H
J Gastroenterol Hepatol; 2017 Oct; 32(10):1769-1777. PubMed ID: 28168749
[TBL] [Abstract][Full Text] [Related]
9. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice.
Liu CH; Chern GJ; Hsu FF; Huang KW; Sung YC; Huang HC; Qiu JT; Wang SK; Lin CC; Wu CH; Wu HC; Liu JY; Chen Y
Hepatology; 2018 Mar; 67(3):899-913. PubMed ID: 28885731
[TBL] [Abstract][Full Text] [Related]
10. Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches.
Wang X; Tai Z; Zhang W; Gao S
Curr Gene Ther; 2015; 15(2):120-41. PubMed ID: 25537775
[TBL] [Abstract][Full Text] [Related]
11. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma.
Zamboni CG; Kozielski KL; Vaughan HJ; Nakata MM; Kim J; Higgins LJ; Pomper MG; Green JJ
J Control Release; 2017 Oct; 263():18-28. PubMed ID: 28351668
[TBL] [Abstract][Full Text] [Related]
12. A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma.
Zhang MY; Wang JP
Tumour Biol; 2017 Apr; 39(4):1010428317698341. PubMed ID: 28443470
[TBL] [Abstract][Full Text] [Related]
13. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC).
Rajasekaran D; Srivastava J; Ebeid K; Gredler R; Akiel M; Jariwala N; Robertson CL; Shen XN; Siddiq A; Fisher PB; Salem AK; Sarkar D
Bioconjug Chem; 2015 Aug; 26(8):1651-61. PubMed ID: 26079152
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
16. Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo.
Sun XY; Wu ZD; Hu JB
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):373-7. PubMed ID: 14607709
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.
Galal El-Shemi A; Mohammed Ashshi A; Oh E; Jung BK; Basalamah M; Alsaegh A; Yun CO
Gene Ther; 2018 Jan; 25(1):54-65. PubMed ID: 28925992
[TBL] [Abstract][Full Text] [Related]
18. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
19. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Guo Y; Wang J; Zhang L; Shen S; Guo R; Yang Y; Chen W; Wang Y; Chen G; Shuai X
Hepatology; 2016 Apr; 63(4):1240-55. PubMed ID: 26680504
[TBL] [Abstract][Full Text] [Related]
20. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
